Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems

Journal of Controlled Release

Volumn 171, Issue 1, 2013, Pages 17-23

  Kozlovskaya, Luba ^a   Stepensky, David ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Brain drug delivery and targeting; Drug conjugates; Liposomes; Nano drug delivery systems; Nanoparticles

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DOSAGE; EFFICIENCY; LIPOSOMES; NANOPARTICLES; SEARCH ENGINES;

BRAIN DRUG DELIVERIES; CONCENTRATION RATIO; DRUG DELIVERY SYSTEM; DRUG-CONJUGATES; EXPERIMENTAL SETTINGS; NANO-DELIVERY SYSTEMS; QUANTITATIVE ASSESSMENTS; SYSTEMIC ADMINISTRATION;

TARGETED DRUG DELIVERY;

LIPOSOME; NANOPARTICLE; SURFACTANT;

ALLERGIC ENCEPHALOMYELITIS; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; BRAIN TISSUE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; DRUG CONCENTRATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR PHAGOCYTE; NANOENCAPSULATION; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

BRAIN DRUG DELIVERY AND TARGETING; DRUG CONJUGATES; LIPOSOMES; NANO-DRUG DELIVERY SYSTEMS; NANOPARTICLES;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84885145148     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.06.028     Document Type: Review

References (38)

1. W.M. Pardridge, Blood-brain barrier drug targeting: the future of brain drug development, Mol. Interv. 3 (2003) 90-105, (151).
2. W.M. Pardridge, Drug targeting to the brain, Pharm. Res. 24 (2007) 1733-1744. (Pubitemid 47206623)
3. A. Beduneau, P. Saulnier, J.P. Benoit, Active targeting of brain tumors using nanocarriers, Biomaterials 28 (2007) 4947-4967. (Pubitemid 47362345)
4. D.J. Begley, Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmacol. Ther. 104 (2004) 29-45. (Pubitemid 39410561)
5. W.M. Pardridge, Biopharmaceutical drug targeting to the brain, J. Drug Target 18 (2010) 157-167.
6. W.M. Pardridge, R.J. Boado, Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier, Methods Enzymol. 503 (2012) 269-292.
7. P. Vlieghe, M. Khrestchatisky, Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery, Med. Res. Rev. 33 (2012) 457-516.
8. S. Wohlfart, S. Gelperina, J. Kreuter, Transport of drugs across the blood-brain barrier by nanoparticles, J. Control. Release 161 (2012) 264-273.
9. P. Ruenraroengsak, J.M. Cook, AT. Florence, Nanosystem drug targeting: facing up to complex realities, J. Control. Release 141 (2010) 265-276.
10. Y.H. Bae, K. Park, Targeted drug delivery to tumors: myths, reality and possibility, J. Control. Release 153 (2011) 198-205.
11. AT. Florence, Reductionism and complexity in nanoparticle-vectored drug targeting, J. Control. Release 161 (2012) 399-402.
12. AT. Florence, "Targeting," nanoparticles: the constraints of physical laws and physical barriers, J. Control. Release 164 (2012) 115-124.
13. S. Muro, Challenges in design and characterization of ligand-targeted drug delivery systems, J. Control. Release 164 (2012) 125-137.
14. K. Petrak, Targeted drug delivery-Quo Vadis? Drug Dev. Res. 73 (2012) 59-65.
15. A. Koshkaryev, R. Sawant, M. Deshpande, V. Torchilin, Immunoconjugates and long circulating systems: origins, current state of the art and future directions, Adv. Drug Deliv. Rev. 65 (2013) 24-35.
16. W.M. Pardridge, shRNA and siRNA delivery to the brain, Adv. Drug Deliv. Rev. 59 (2007) 141-152. (Pubitemid 46773051)
17. R.J. Boado, W.M. Pardridge, The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier, J. Drug Deliv. 2011 (2011) 296151.
18. V.P. Torchilin, Drug targeting, Eur. J. Pharm. Sci. 11 (Suppl. 2) (2000) S81-S91.
19. J. Lichota, T. Skjorringe, LB. Thomsen, T Moos, Macromolecular drug transport into the brain using targeted therapy, J. Neurochem. 113 (2010) 1-13.
20. I. van Rooy, S. Cakir-Tascioglu, W.E. Hennink, G. Storm, R.M. Schiffelers, E. Mastrobattista, In vivo methods to study uptake of nanoparticles into the brain, Pharm. Res. 28 (2011) 456-471.
21. A.D. Corlan, Medline trend: automated yearly statistics of PubMed results for any query. Web resource at URL: http://dan.corlan.net/medline-trend.html, 2004, (Accessed: 2012-02-25).
22. B. Davies, T Morris, Physiological parameters in laboratory animals and humans, Pharm. Res. 10 (1993) 1093-1095. (Pubitemid 23211439)
23. J.J. Lochhead, R.G. Thorne, Intranasal delivery of biologics to the central nervous system, Adv. Drug Deliv. Rev. 64 (2012) 614-628.
24. A. Misra, G. Kher, Drug delivery systems from nose to brain, Curr. Pharm. Biotechnol. 13 (2012) 2355-2379.
25. Y. Liu, Y.C. Tseng, L. Huang, Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res. 29 (2012) 3273-3277.
26. S.M. Moghimi, A.C. Hunter, TL. Andresen, Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective, Annu. Rev. Pharmacol. Toxicol. 52 (2011) 481-503.
27. A.J. North, Seeing is believing? A beginners' guide to practical pitfalls in image acquisition, J. Cell Biol. 172 (2006) 9-18. (Pubitemid 43042625)
28. J.C. Waters, Accuracy and precision in quantitative fluorescence microscopy, J. Cell Biol. 185 (2009) 1135-1148.
29. Y.S. Kang, W.M. Pardridge, Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate, J. Pharmacol. Exp. Ther. 269 (1994) 344-350. (Pubitemid 24143273)
30. HJ. Lee, R.J. Boado, DA Braasch, D.R. Corey, W.M. Pardridge, Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology, J. Nucl. Med. 43 (2002) 948-956. (Pubitemid 34747821)
31. R.J. Boado, Q.H. Zhou, J.Z. Lu, E.K. Hui, W.M. Pardridge, Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor, Mol. Pharm. 7 (2010) 237-244.
32. N. Weiss, F. Miller, S. Cazaubon, P.O. Couraud, The blood-brain barrier in brain homeostasis and neurological diseases, Biochim. Biophys. Acta 1788 (2009) 842-857.
33. K. Karolczak, S. Rozalska, M. Wieczorek, M. Labieniec-Watala, C. Watala, Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired blood-brain barrier permeability in streptozotocin diabetes in rats, Int. J. Pharm. 436 (2012) 508-518.
34. Y. Chassidim, R. Veksler, S. Lublinsky, G.S. Pell, A. Friedman, I. Shelef, Quantitative imaging assessment of blood-brain barrier permeability in humans, Fluids Barriers CNS 10 (2013) 9.
35. S. Taurin, H. Nehoff, K. Greish, Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control. Release 164 (2012) 265-275.
36. D.Y. Arifin, K.Y. Lee, C.H. Wang, Chemotherapeutic drug transport to brain tumor, J. Control. Release 137 (2009) 203-210.
37. Y. Liu, S. Paliwal, K.S. Bankiewicz, J.R. Bringas, G. Heart, S. Mitragotri, M.R. Prausnitz, Ultrasound-enhanced drug transport and distribution in the brain, AAPS PharmSciTech 11 (2010) 1005-1017.
38. A.J. Torres, C. Zhu, M.L. Shuler, S. Pannullo, Paclitaxel delivery to brain tumors from hydrogels: a computational study, Biotechnol. Prog. 27 (2011) 1478-1487.